Masitinib monotherapy in canine epitheliotropic lymphoma

N Holtermann; M Kiupel; M Kessler; E Teske; D Betz; J Hirschberger

doi:10.1111/vco.12157

Masitinib monotherapy in canine epitheliotropic lymphoma

N Holtermann, M Kiupel, M Kessler, E Teske, D Betz, J Hirschberger

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

This study evaluated efficacy and side effects of masitinib in canine epitheliotropic lymphoma. Complete remission occurred in 2 of 10 dogs and lasted for median 85 days. Five dogs went into partial remission for median 60.5 days. Three pretreated dogs did not respond to therapy. Side effects occurred in six dogs and were mostly mild to moderate. Immunohistochemistry was available for eight dogs. KIT receptor was negative in all of them, six of eight lymphomas stained strongly positive for stem cell factor (SCF). platelet-derived growth factor (PDGF)-AA was weakly positive in two and negative in six. PDGF-BB was negative in four tumours, weakly positive in one and strongly positive in three. One was strongly positive for PDGF receptor (PDGFR)-β, seven were negative for that receptor. Five showed strong expression of PDGFR-α, two showed weak expression, one was negative. In conclusion, masitinib is effective in treating canine epitheliotropic lymphoma. But its effects are most likely not generated through the KIT receptor.

Original language	English
Number of pages	9
Journal	Veterinary and Comparative Oncology
DOIs	https://doi.org/10.1111/vco.12157
Publication status	Published - 14 Sept 2015

Bibliographical note

Access to Document

10.1111/vco.12157

HoltermannFinal published version, 155 KBLicence: Taverne

Cite this

@article{d5cdae8eb8614299aba68c0e1b4f3df4,

title = "Masitinib monotherapy in canine epitheliotropic lymphoma",

abstract = "This study evaluated efficacy and side effects of masitinib in canine epitheliotropic lymphoma. Complete remission occurred in 2 of 10 dogs and lasted for median 85 days. Five dogs went into partial remission for median 60.5 days. Three pretreated dogs did not respond to therapy. Side effects occurred in six dogs and were mostly mild to moderate. Immunohistochemistry was available for eight dogs. KIT receptor was negative in all of them, six of eight lymphomas stained strongly positive for stem cell factor (SCF). platelet-derived growth factor (PDGF)-AA was weakly positive in two and negative in six. PDGF-BB was negative in four tumours, weakly positive in one and strongly positive in three. One was strongly positive for PDGF receptor (PDGFR)-β, seven were negative for that receptor. Five showed strong expression of PDGFR-α, two showed weak expression, one was negative. In conclusion, masitinib is effective in treating canine epitheliotropic lymphoma. But its effects are most likely not generated through the KIT receptor.",

author = "N Holtermann and M Kiupel and M Kessler and E Teske and D Betz and J Hirschberger",

note = "{\textcopyright} 2015 John Wiley & Sons Ltd.",

year = "2015",

month = sep,

day = "14",

doi = "10.1111/vco.12157",

language = "English",

journal = "Veterinary and Comparative Oncology",

issn = "1476-5810",

publisher = "Wiley-Blackwell Publishing Ltd",

}

TY - JOUR

T1 - Masitinib monotherapy in canine epitheliotropic lymphoma

AU - Holtermann, N

AU - Kiupel, M

AU - Kessler, M

AU - Teske, E

AU - Betz, D

AU - Hirschberger, J

PY - 2015/9/14

Y1 - 2015/9/14

N2 - This study evaluated efficacy and side effects of masitinib in canine epitheliotropic lymphoma. Complete remission occurred in 2 of 10 dogs and lasted for median 85 days. Five dogs went into partial remission for median 60.5 days. Three pretreated dogs did not respond to therapy. Side effects occurred in six dogs and were mostly mild to moderate. Immunohistochemistry was available for eight dogs. KIT receptor was negative in all of them, six of eight lymphomas stained strongly positive for stem cell factor (SCF). platelet-derived growth factor (PDGF)-AA was weakly positive in two and negative in six. PDGF-BB was negative in four tumours, weakly positive in one and strongly positive in three. One was strongly positive for PDGF receptor (PDGFR)-β, seven were negative for that receptor. Five showed strong expression of PDGFR-α, two showed weak expression, one was negative. In conclusion, masitinib is effective in treating canine epitheliotropic lymphoma. But its effects are most likely not generated through the KIT receptor.

AB - This study evaluated efficacy and side effects of masitinib in canine epitheliotropic lymphoma. Complete remission occurred in 2 of 10 dogs and lasted for median 85 days. Five dogs went into partial remission for median 60.5 days. Three pretreated dogs did not respond to therapy. Side effects occurred in six dogs and were mostly mild to moderate. Immunohistochemistry was available for eight dogs. KIT receptor was negative in all of them, six of eight lymphomas stained strongly positive for stem cell factor (SCF). platelet-derived growth factor (PDGF)-AA was weakly positive in two and negative in six. PDGF-BB was negative in four tumours, weakly positive in one and strongly positive in three. One was strongly positive for PDGF receptor (PDGFR)-β, seven were negative for that receptor. Five showed strong expression of PDGFR-α, two showed weak expression, one was negative. In conclusion, masitinib is effective in treating canine epitheliotropic lymphoma. But its effects are most likely not generated through the KIT receptor.

U2 - 10.1111/vco.12157

DO - 10.1111/vco.12157

M3 - Article

C2 - 26364581

SN - 1476-5810

JO - Veterinary and Comparative Oncology

JF - Veterinary and Comparative Oncology

ER -

Masitinib monotherapy in canine epitheliotropic lymphoma

Abstract

Bibliographical note

Access to Document

Fingerprint

Cite this